Colgate-Palmolive (CL) director buys 289 shares at $82.13
John P. Bilbrey, a director of Colgate-Palmolive Company (CL), reported an acquisition on 10/01/2025 of 289 shares of the issuer's common stock at a price of $82.13 per share.
Rhea-AI Filing Summary
John P. Bilbrey, a director of Colgate-Palmolive Company (CL), reported an acquisition on 10/01/2025 of 289 shares of the issuer's common stock at a price of $82.13 per share. Following the transaction, Mr. Bilbrey directly beneficially owns 36,658 shares and indirectly owns 4,719 shares through a trust. The filing states the reason for the acquisition: a portion of his annual cash retainer was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors, resulting in the issuance of common stock.
The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025. No derivative transactions, dispositions, or other changes are disclosed in this Form 4.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 289 | $82.13 | $24K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Colgate-Palmolive director John P. Bilbrey report (CL)?
When was the Form 4 filed and who signed it?
Were there any derivative securities or dispositions reported in this Form 4 for CL?
AI-generated analysis. How Rhea-AI works. Not financial advice.